Dermal Mycosis Pipeline Analysis Report 2026

Report Coverage

The Dermal Mycosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into dermal mycosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dermal mycosis. The dermal mycosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dermal mycosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dermal mycosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dermal mycosis.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Dermal Mycosis Pipeline Outlook

The dermal mycosis pipeline is expected to remain focused on topical and localized antifungal therapies for tinea infections, otomycosis, and symptom relief. The FDA approval of Clotic in September 2025, for fungal otitis externa caused by Aspergillus and Candida species. DailyMed’s May 2026 RoyceDerm Tinea Antifungal Cream label also reflects continued OTC availability of miconazole for athlete’s foot, ringworm, and jock itch, supporting steady demand for accessible azole-based treatments and localized fungal infection management.

Dermal Mycosis Epidemiology

Dermal mycosis remains one of the most common skin infections, mainly covering dermatophyte infections such as tinea corporis, tinea pedis, tinea cruris, scalp ringworm, and onychomycosis. WHO reported in June 2025 that ringworm accounts for roughly half of the estimated 650 million fungal skin infections worldwide. A 2024 GBD-based analysis estimated fungal skin disease prevalence at 1.65 billion cases globally in 2019, with an age-standardized prevalence rate of 21.4%. Cases are higher in warm, humid regions, children, older adults, and immunocompromised patients.

Dermal Mycosis – Pipeline Therapeutic Assessment

Dermal Mycosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, the pipeline is dominated by Phase II candidates (57.58%), followed by Phase I (30.30%), Early Phase I (6.06%), and Phase III (3.03%). Phase IV also accounts for 3.03%, reflecting a strong emphasis on mid-stage clinical development with relatively few late-stage and post-marketing candidates.

Dermal Mycosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the dermal mycosis pipeline analysis include small molecules, biologicals, and peptides. The dermal mycosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dermal mycosis. In September 2025, the FDA approved Clotic (clotrimazole) otic solution) from Laboratorios Salvat for fungal otitis externa, or otomycosis, caused by Aspergillus and Candida species in adults aged 18 years and older.

Dermal Mycosis Clinical Trials – Key Players

The EMR report for the dermal mycosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dermal mycosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dermal mycosis clinical trials:

• Virogen Biotechnology Inc.
• SciTech Development, Inc.
• Prescient Therapeutics, Ltd.
• Sinomune Pharmaceutical Co., Ltd.
• Bristol-Myers Squibb
• Kyowa Kirin, Inc.
• Dizal Pharmaceuticals
• Seagen Inc.
• Merck Sharp & Dohme LLC
• Novartis
• Pfizer
• Mallinckrodt, Inc.

Dermal Mycosis – Emerging Drugs Profile

Key Questions Answered in the Dermal Mycosis Pipeline Insight Report

• Which companies/institutions are leading the dermal mycosis drug development?
• Which company is leading the dermal mycosis pipeline development activities?
• What is the current dermal mycosis commercial assessment?
• What are the opportunities and challenges present in the dermal mycosis pipeline landscape?
• What is the efficacy and safety profile of dermal mycosis pipeline drugs?
• Which company is conducting major trials for dermal mycosis drugs?
• Which companies/institutions are involved in dermal mycosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in dermal mycosis?

Reasons To Buy This Report

The Dermal Mycosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dermal mycosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dermal mycosis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Dermal Mycosis Epidemiology Forecast

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

Epidermal Growth Factor Receptor Antagonists Market